The Motley Fool Discussion Boards

Previous Page

International Investing / Australia (All-Ordinaries)

URL:  https://boards.fool.com/demiller-to-the-point-a-separate-research-and-12267225.aspx

Subject:  Re: Novogen Date:  3/23/2000  7:31 PM
Author:  Lems Number:  1256 of 6186


demiller:
To the point - a separate research and scientific analysis was done on the drug and it was found NOT to do what Novogen (and the initial independent report) said it would do.

The drug has since been withdrawn from sale.



This is the first time I've heard about Novogen having had a drug on the market. As far as I know they only sell food-supplements that do not require scientific testing. But Novogen's supplements are scientifically tested anyway. In more than 30 studies world-wide, in independent university hospitals. The first drug in the pipeline is only in clinical phase 1.

Novogen has made a mistake claiming independent scientific research in their ads before this research was peer-reviewed and published. As far as I know, only the advertisement has been pulled, not the supplement.

My stake in Novogen is only a small portion of my total investments and I'm well diversified. Some stocks I sell and move onto something else, some others, where i expect (or sometimes merely hope for) enormous growth opportunities in the long run, i keep and don't worry about price fluctuations or minor set-backs. Novogen's price is just back where it was about a month ago, before it started going up as a result of the heavy advertising.

eveline



Copyright 1996-2022 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us